Recursion to buy AI-enabled drug discovery startups Cyclica, Valence
Recursion agreed to buy Toronto-based Cyclica for $40 million and Montreal-based Valence for $47.5 million.
Recursion agreed to buy Toronto-based Cyclica for $40 million and Montreal-based Valence for $47.5 million.
Copyright PEI Media
Not for publication, email or dissemination